Rising Incidence Of Chronic Diseases Driving The Generic Pharmaceuticals Is Supporting Expansion In The RNA Targeting Small Molecule Drug Discovery Market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The RNA Targeting Small Molecule Drug Discovery Market Expected To Reach Based On Its 2026 Value?
The rna targeting small molecule drug discovery market has seen substantial expansion in recent years. This market is set to increase from $2.13 billion in 2025 to $2.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.3%. The historical period’s growth can be linked to the restricted druggability of protein targets, a rising occurrence of genetic disorders, progress in rna biology research, an increase in academic-industry collaborations, and the early achievements of rna-based therapeutics.
The rna targeting small molecule drug discovery market size is projected to experience substantial growth in the coming years. This market is expected to expand to $6.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. The projected increase during this period stems from advancements such as AI-enabled rna target identification, heightened investment in precision medicine, the expansion of rna therapeutics pipelines, enhanced rna delivery technologies, and supportive regulatory frameworks for innovative modalities. Prominent trends anticipated within this forecast timeframe include AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, improvements in rna-specific small molecule libraries, better rna binding selectivity and specificity, and the integration of multi-omics in rna drug discovery efforts.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp
Which Key Drivers Are Affecting The RNA Targeting Small Molecule Drug Discovery Market Development?
The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising prevalence of cancer, genetic disorders, and viral infections. Cancer is a group of diseases marked by uncontrolled cell proliferation, while viral infections are caused by tiny infectious agents, viruses, that replicate solely inside living cells. RNA targeting-based drug discovery is utilized to treat these conditions because they involve genes and malfunctioning genetic material, making them amenable to treatment through RNA targeting methods. For example, in February 2024, a report from the Switzerland-based World Health Organization (WHO) revealed an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most frequent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are anticipated to increase by 77%, exceeding 35 million annually. Consequently, the increasing occurrence of cancer, genetic disorders, and viral infections serves as a key driver for the growth of the RNA-targeted small-molecule drug discovery market.
How Is Segmentation Applied In The RNA Targeting Small Molecule Drug Discovery Market Segment Analysis?
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA
Which Trends Are Shaping Growth In The RNA Targeting Small Molecule Drug Discovery Market?
Major companies in the RNA-targeting small-molecule drug discovery market are developing innovative platforms, such as software-as-a-service (SaaS) solutions, to gain a competitive edge. SaaS is a software distribution model where applications are hosted by a third-party provider and delivered to customers over the Internet. For instance, in December 2023, the U.S.-based science and technology company Merck & Co. Inc. launched AIDDISON. This platform proposes the most effective methods for synthesizing selected medications. This innovative strategy could lead to significant cost reductions in the drug discovery process and greatly enhance the success rate of introducing new medicines to patients. By connecting virtual molecular design with real-world manufacturability, the platform improves the success rate of delivering cutting-edge treatments to patients through extracting concealed insights from vast datasets. To accelerate the medication development process, this novel AI system integrates computer-aided drug design, machine learning, and generative AI.
Who Are The Companies Participating In The RNA Targeting Small Molecule Drug Discovery Market Environment?
Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
Get The Full RNA Targeting Small Molecule Drug Discovery Market Report:
Which Geographic Region Dominates The RNA Targeting Small Molecule Drug Discovery Market?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized RNA Targeting Small Molecule Drug Discovery Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company
Rna Targeting Small Molecule Drug Discovery Market Report 2026
Rna Targeting Small Molecules Therapeutics Market Report 2026
Small Molecule Drug Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
